Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.

US-based gene therapy developer 4D Molecular Therapeutics (4DMT) refiled for an initial public offering on Tuesday, giving Berkeley Catalyst Fund, a venture unit aligned with University of California, the chance to exit. The company has filed to raise up to $75m in an offering on the Nasdaq Global Market, the same market where it originally…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.